Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 10:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 104 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Healthy Japanese Volunteers Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Lebrikizumab in Healthy Japanese and Caucasian Volunteers

NCT01423318
View directory record Official record
Conditions
Healthy Volunteer
Interventions
lebrikizumab, placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 23, 2026, 10:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Dose Escalation Study of Plerixafor in Healthy Subjects of Japanese Descent

NCT01579149
View directory record Official record
Conditions
Healthy Volunteer
Interventions
plerixafor, Placebo
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
20 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Mar 22, 2015 · Synced Sep 23, 2026, 10:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Food on PC14586 in Healthy Volunteers and the PK of PC14586 in Healthy Japanese Volunteers

NCT05249348
View directory record Official record
Conditions
Healthy Volunteers
Interventions
PC14586
Drug
Lead sponsor
PMV Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced Sep 23, 2026, 10:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Investigate Palbociclib (PD-0332991) Pharmacokinetics In Healthy Subjects Of Japanese Descent Relative To Healthy Non-Asian Subjects, And To Determine If Changes In Palbociclib Dose Result In Proportional Changes In Palbociclib Plasma Exposure In Japanese Subjects

NCT02059330
View directory record Official record
Conditions
Healthy
Interventions
Palbociclib 75mg, Palbociclib 125mg, Palbociclib 100mg, Palbociclib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 23, 2014 · Synced Sep 23, 2026, 10:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants

NCT06674941
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Teprotumumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Sep 23, 2026, 10:23 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study of the Safety, Tolerability, and Pharmacokinetics of REGN6490 in Healthy Japanese Adult Volunteers

NCT04616105
View directory record Official record
Conditions
Healthy Volunteer
Interventions
REGN6490, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
20 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Sep 23, 2026, 10:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Pharmacokinetics of Intranasally Administered Esketamine in Healthy Japanese and Caucasian Volunteers

NCT01980303
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Esketamine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
20 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Sep 23, 2026, 10:23 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Study of LY5625575 in Healthy Participants and in Participants With Inflammation (Elevated C-Reactive Protein)

NCT07801300
View directory record Official record
Conditions
Healthy Volunteers, C-Reactive Protein
Interventions
LY5625575, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
2
States / cities
Miami, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 23, 2026, 10:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Oral Dose of 4 mg Cenerimod in Healthy Japanese and Caucasian Subjects

NCT04052360
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Cenerimod, Matching Placebo
Drug
Lead sponsor
Viatris Innovation GmbH
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Sep 23, 2026, 10:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants

NCT05229562
View directory record Official record
Conditions
Healthy Volunteer
Interventions
BIIB122
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Sep 23, 2026, 10:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate Safety, Tolerability & PK of rhNGF in Healthy Volunteers

NCT03836859
View directory record Official record
Conditions
Healthy Volunteers
Interventions
rhNGF 20μg/mL, Placebo
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Dec 25, 2023 · Synced Sep 23, 2026, 10:23 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.

NCT07514260
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-295, Placebo for ABBV-295
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 23, 2026, 10:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-99677 in Healthy Adult Japanese Participants.

NCT04958291
View directory record Official record
Conditions
Healthy Volunteers
Interventions
CC-99677, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 55 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Sep 23, 2026, 10:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Maribavir Administered in Healthy Japanese Participants Compared With Matched, Healthy, Non-Hispanic, Caucasian Participants and to Assess Dose-Proportionality of 3 Doses of Maribavir in Japanese Participants

NCT04497883
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Maribavir (400 mg), Maribavir (200 mg), Maribavir (800 mg)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 23, 2026, 10:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects

NCT01291602
View directory record Official record
Conditions
Healthy Male and Female Japanese Volunteers
Interventions
NXL104, CAZ104, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
20 Years to 45 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
2
States / cities
Glendale, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Sep 23, 2026, 10:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

PK Study of PT003 and PT001 in Japanese Healthy Subjects

NCT02196714
View directory record Official record
Conditions
COPD
Interventions
Glycopyrronium and Formoterol Fumarate (GFF) Dose 1, Glycopyrronium and Formoterol Fumarate (GFF) Dose 2, Glycopyrronium (GP) Dose 1, Glycopyrronium (GP) Dose 2
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Sep 23, 2026, 10:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Single Dose Inclacumab in Japanese Healthy Volunteers Compared to Caucasian Healthy Volunteers

NCT01815827
View directory record Official record
Conditions
Healthy Volunteer
Interventions
inclacumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 23, 2026, 10:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of RO5024048 in Japanese and Caucasian Healthy Volunteers

NCT01152671
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Placebo, RO5024048
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
20 Years to 55 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
2
States / cities
Glendale, California • Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Sep 23, 2026, 10:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Compare the Level of Elafibranor in Blood After Repeat Administration in Japanese and Non-Asian Healthy Participants

NCT05543369
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Elafibranor
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Long Beach, California • Los Alamitos, California
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Sep 23, 2026, 10:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics and Pharmacodynamic of AZD1722 in Healthy Male and Female Japanese Subjects

NCT02176252
View directory record Official record
Conditions
Healthy Volunteer
Interventions
AZD1722, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
19 Years to 65 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2014 · Synced Sep 23, 2026, 10:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD5055 in Japanese and Chinese Healthy Volunteers..

NCT05955183
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD5055, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 7, 2023 · Synced Sep 23, 2026, 10:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety and Tolerability After Single Oral Dosing of AZD1656 in Japanese Healthy Volunteers

NCT00741689
View directory record Official record
Conditions
Healthy Volunteers
Interventions
AZD1656
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 40 Years · Male only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2010 · Synced Sep 23, 2026, 10:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Ethnobridging TriaL of AGA2118 in Healthy Japanese, Chinese, and Caucasian ParticipantS (ATLAS)

NCT07361354
View directory record Official record
Conditions
Healthy Participants, Pharmacokinetic Study
Interventions
AGA2118
Drug
Lead sponsor
Angitia Incorporated Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 23, 2026, 10:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GDC-0853 in Healthy Japanese and Caucasian Participants

NCT03188783
View directory record Official record
Conditions
Healthy Volunteer
Interventions
GDC-0853, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Sep 23, 2026, 10:23 AM EDT